TY - JOUR
T1 - The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma
T2 - a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)
AU - Annibali, Ombretta
AU - Hohaus, Stefan
AU - Marchesi, Francesco
AU - Cantonetti, Maria
AU - Di Rocco, Alice
AU - Tomarchio, Valeria
AU - Di Napoli, Arianna
AU - Pelliccia, Sabrina
AU - Battistini, Roberta
AU - Anticoli Borza, Paola
AU - Abruzzese, Elisabetta
AU - Cenfra, Natalia
AU - Andriani, Alessandro
AU - Tesei, Cristiano
AU - Alma, Eleonora
AU - Palombi, Francesca
AU - Pupo, Livio
AU - Petrucci, Luigi
AU - Becilli, Marco
AU - Maiolo, Elena
AU - Bellesi, Silvia
AU - Cuccaro, Annarosa
AU - D’Alò, Francesco
AU - Cox, Maria Christina
PY - 2019/12/6
Y1 - 2019/12/6
N2 - In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).
AB - In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).
KW - cancer
KW - DLBCL
KW - lymphoma
KW - N/L ratio
KW - R-CHOP
UR - http://www.scopus.com/inward/record.url?scp=85068530187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068530187&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1633628
DO - 10.1080/10428194.2019.1633628
M3 - Article
C2 - 31259651
AN - SCOPUS:85068530187
VL - 60
SP - 3386
EP - 3394
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 14
ER -